S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act


Feb 8, 2016
114th Congress, 2015–2017


Enacted — Signed by the President on Apr 19, 2016

This bill was enacted after being signed by the President on April 19, 2016.


Pub.L. 114-146


Alan “Al” Franken

Junior Senator from Minnesota



Read Text »
Last Updated: Apr 14, 2016
Length: 1 pages

About the bill

Full Title

A bill to expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

Read CRS Summary >


Feb 8, 2016

This is the first step in the legislative process.

Mar 9, 2016
Reported by Committee

A committee has issued a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Mar 17, 2016
Passed Senate

The bill was passed in a vote in the Senate. It goes to the House next. The vote was by Unanimous Consent so no record of individual votes was made.

Apr 12, 2016
Passed House

The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill. The vote was by voice vote so no record of individual votes was made.

Apr 19, 2016
Enacted — Signed by the President

The President signed the bill and it became law.

This page is about a bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Links & tools

Primary Source


Congress.gov is updated generally one day after events occur. Legislative activity since the last update may not be reflected on GovTrack. Data via congress project.


Click a format for a citation suggestion: